- Raw materials
- Antibacterials
- Ticarcillin
Ticarcillin API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Ticarcillin | CAS No: 34787-01-4 | GMP-certified suppliers
A medication that treats a broad range of bacterial infections, providing extended-spectrum antibacterial activity against susceptible aerobic and anaerobic pathogens in systemic use.
Therapeutic categories
Primary indications
- For the treatment of bacterial infections
Product Snapshot
- Ticarcillin is supplied as an injectable small molecule antibiotic available in powder and solution formulations for intravenous and intramuscular administration
- It is primarily indicated for the treatment of bacterial infections
- The product holds approval in the US and Canada, including veterinary approval and investigational status in certain markets
Clinical Overview
Clinically, ticarcillin is indicated for the treatment of bacterial infections caused by susceptible organisms. It exhibits broad-spectrum bactericidal activity against various aerobic and anaerobic gram-positive and gram-negative bacteria. However, its efficacy is reduced against bacteria that produce beta-lactamase enzymes, as these enzymes hydrolyze the beta-lactam ring, leading to antibiotic degradation.
The mechanism of action of ticarcillin involves inhibition of bacterial cell wall synthesis. Specifically, it prevents the cross-linking of peptidoglycan chains, an essential process for maintaining cell wall integrity during bacterial replication. This disruption results in bacterial cell lysis and death during cell division.
Pharmacokinetic data indicate that ticarcillin is typically administered parenterally, with distribution occurring widely in body tissues and fluids. It is primarily eliminated by renal excretion, thus dose adjustments may be necessary in patients with impaired kidney function. The drug’s absorption and metabolic profile supports its use in systemic infections.
Safety considerations include the potential for hypersensitivity reactions common to beta-lactam antibiotics, gastrointestinal disturbances, and the risk of superinfection with resistant organisms upon prolonged therapy. Monitoring for signs of allergic reaction and adjusting therapy based on culture and sensitivity results are recommended.
Ticarcillin is approved for human and veterinary use in various regions. It is often combined with beta-lactamase inhibitors in clinical practice to extend its spectrum of activity.
For API procurement, quality assurance should confirm compliance with pharmacopeial standards for identity, purity, and potency. The presence of residual solvents, impurities, and microbial contamination must be within specified limits. Reliable sourcing from manufacturers with validated synthetic processes and documented stability data is critical to ensure consistent performance in pharmaceutical formulations.
Identification & chemistry
| Generic name | Ticarcillin |
|---|---|
| Molecule type | Small molecule |
| CAS | 34787-01-4 |
| UNII | F93UJX4SWT |
| DrugBank ID | DB01607 |
Pharmacology
| Summary | Ticarcillin is a semisynthetic antibiotic that inhibits bacterial cell wall synthesis by preventing peptidoglycan cross-linking, leading to cell death during division. It exhibits broad-spectrum bactericidal activity against various gram-positive and gram-negative aerobic and anaerobic bacteria. Its primary target is penicillin-binding protein 2a, though its efficacy is limited by susceptibility to β-lactamase–producing organisms. |
|---|---|
| Mechanism of action | Ticarcillin's principal mechanism of action revolves around its capacity to prevent the cross-linking of peptidoglycan during bacterial cell wall synthesis. Consequently, when the offending bacteria attempt to undergo cell division, cell death occurs. |
| Pharmacodynamics | Ticarcillin is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative aerobic and anaerobic bacteria. Ticarcillin is, however, susceptible to degradation by ß-lactamases, and therefore, the spectrum of activity does not normally include organisms which produce these enzymes. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Penicillin binding protein 2a | Staphylococcus aureus | inhibitor |
ADME / PK
| Half-life | 1.1 hours |
|---|---|
| Protein binding | 45% |
Formulation & handling
- Ticarcillin is a small molecule dipeptide antibiotic primarily formulated as a powder for injection, suitable for intravenous and intramuscular administration.
- The API has low water solubility (approx. 0.07 g/L) and must be reconstituted before use, with attention to solution stability post-preparation.
- Given its peptide bond structure, maintain controlled storage conditions to prevent hydrolysis and ensure potency during handling and formulation.
Regulatory status
| Lifecycle | The API’s primary patents have expired in the US and Canada, allowing for generic manufacturing and distribution. Consequently, the product is in a mature market phase with established competition. |
|---|
| Markets | US, Canada |
|---|
Supply Chain
| Supply chain summary | Ticarcillin is supplied by multiple originator companies with branded products primarily available in the US and Canadian markets. The presence of established brand names such as Ticar and Timentin indicates a well-defined product portfolio. Patent expirations have likely enabled or will enable generic competition in these markets. |
|---|
Safety
| Toxicity | As with other penicillins, neurotoxic reactions may arise when very high doses of ticarcillin are administered, especially in patients with impaired renal function. |
|---|
- Use caution when handling to prevent exposure, as high doses may induce neurotoxic effects
- Monitor for contamination risk due to potential impact on renal-compromised subjects
- Follow appropriate protocols to avoid environmental release and ensure safe disposal
Ticarcillin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
